Solid Tumors
Conditions
Interventions
imaging cohort:89Zr-CTB006 PET/CT
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Subjects aged between 18 and 75 years old (including 18 and 75 years old), male and female; 2. Patients with solid tumors such as esophageal tumor, gastrointestinal tumor, liver tumor and pancreatic tumor, or suspected patients with solid tumors such as esophageal tumor, gastrointestinal tumor, liver tumor and pancreatic tumor, who plan to undergo pathological biopsy or tumor surgery; 3. Subjects with ECoG score of 0-1 (see Annex 1 for ECoG score table); 4. Patients with expected survival >= 12 weeks; 5. Blood routine, coagulation, liver and kidney function meet the following criteria: blood routine: WBC >= 4.0 x 10^9 / L or neutrophils >= 1.5 x 10^9 / L, PLT >= 100 x 10^9 / L, Hb >= 90g / L; Pt or APTT <= 1.5uln; liver and kidney function: T-Bil <= 1.5 x ULN (upper limit of normal value), ALT / AST <= 2.5uln or <= 5 x ULN (liver metastasis subjects), ALP <= 2.5 ULN (ALP <= 4.5uln in case of bone metastasis or liver metastasis); BUN <= 1.5 x ULT, SCr <= 1.5 x ULT. 6. Subjects with at least one measurable target lesion according to RECIST 1.1 standard; 7. Women must take effective contraceptive measures during the study period and within 6 months after the end of the study (effective contraceptive measures refer to sterilization, intrauterine hormone device, condom, contraceptive, abstinence or partner vasectomy, etc.); men should agree to the subjects who must take contraceptive measures during the study period and within 6 months after the end of the study period; 8. The subjects who can understand and sign the informed consent voluntarily have good compliance.
Exclusion criteria
Exclusion criteria: 1.Patients with any of the following conditions include brain metastasis (except primary or metastatic brain tumors without symptoms and requiring treatment), carcinomatous cerebrospinal meningitis, myocardial infarction (within 6 months before enrollment), unstable angina pectoris, or high risk of uncontrollable arrhythmia, coronary artery bypass grafting, cerebrovascular accident (within 6 months before enrollment), and congestive heart disease Heart failure (grade III - IV), pulmonary embolism, deep vein thrombosis, infection requiring intravenous antibiotics within 2 weeks, immunosuppressive therapy after organ transplantation; 2. Patients with primary central nervous system tumors; 3. Subjects with HBV DNA >= 104 copies or >= 2000 IU / ml; 4. Subjects with HCV-RNA >= 1000 copies / ml; 5. HIV antibody or syphilis antibody positive subjects; 6. Patients with acute or subacute intestinal obstruction or history of inflammatory bowel disease; 7. Women in pregnancy, lactation or planned pregnancy; 8. Subjects who are known to be allergic to the test drug or its excipients in the study treatment; 9. Subjects who have a history of psychotropic substance abuse and are unable to quit or have mental disorders; 10. Subjects who could not lie on their back for half an hour; 11. Patients allergic to any component of the imaging agent or antibody; 12. Patients who could not accept PET / CT imaging; 13. Other researchers think that it is not suitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUV; | — |
Countries
China
Contacts
Public ContactYang Zhi
Beijing Cancer Hospital
Outcome results
None listed